S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Elon Musk's mysterious ways on display in Tesla tweet trial
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Elon Musk's mysterious ways on display in Tesla tweet trial
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Elon Musk's mysterious ways on display in Tesla tweet trial
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Elon Musk's mysterious ways on display in Tesla tweet trial
NASDAQ:DCTH

Delcath Systems - DCTH Stock Forecast, Price & News

$3.75
+0.02 (+0.54%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.71
$3.78
50-Day Range
$2.77
$3.92
52-Week Range
$2.34
$7.75
Volume
7,352 shs
Average Volume
16,825 shs
Market Capitalization
$37.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Delcath Systems MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
362.2% Upside
$17.33 Price Target
Short Interest
Bearish
1.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Delcath Systems in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$55,078 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.77) to ($1.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

642nd out of 1,054 stocks

Surgical & Medical Instruments Industry

66th out of 105 stocks


DCTH stock logo

About Delcath Systems (NASDAQ:DCTH) Stock

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

DCTH Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Delcath Systems Closes Private Placement of $6.2 Million
Delcath Shares Climb on $6.2 Million Private Placement
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Delcath Systems Inc. Q3 Loss beats estimates
Delcath Systems to Host Third Quarter 2022 Results
Earnings Outlook For Delcath Systems
See More Headlines
Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

DCTH Company Calendar

Last Earnings
11/08/2022
Today
1/29/2023
Next Earnings (Estimated)
3/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCTH
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.33
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+362.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-25,650,000.00
Net Margins
-757.05%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.56 million
Book Value
$1.62 per share

Miscellaneous

Free Float
8,363,000
Market Cap
$37.69 million
Optionable
Not Optionable
Beta
0.87

Key Executives

  • Mr. Gerard J. Michel MBAMr. Gerard J. Michel MBA (Age 60)
    MS, CEO & Director
    Comp: $683.82k
  • Mr. John Purpura M.S.Mr. John Purpura M.S. (Age 62)
    Chief Operating Officer
    Comp: $482.56k
  • Dr. Johnny John M.D. (Age 59)
    Sr. VP Clinical Devel. & Medical Affairs
    Comp: $383.63k
  • Mr. Anthony C. Dias (Age 56)
    VP of Fin.
  • Mr. David Hoffman
    Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Mr. Robin Wagge
    Sr. VP of Rubenstein Associates
  • Mr. Kevin Muir
    VP of Commercial Operations













DCTH Stock - Frequently Asked Questions

Should I buy or sell Delcath Systems stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCTH shares.
View DCTH analyst ratings
or view top-rated stocks.

What is Delcath Systems' stock price forecast for 2023?

3 brokerages have issued 1-year price targets for Delcath Systems' stock. Their DCTH share price forecasts range from $14.00 to $19.00. On average, they expect the company's share price to reach $17.33 in the next year. This suggests a possible upside of 362.2% from the stock's current price.
View analysts price targets for DCTH
or view top-rated stocks among Wall Street analysts.

How have DCTH shares performed in 2023?

Delcath Systems' stock was trading at $3.60 on January 1st, 2023. Since then, DCTH shares have increased by 4.2% and is now trading at $3.75.
View the best growth stocks for 2023 here
.

When is Delcath Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our DCTH earnings forecast
.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.13. The company had revenue of $0.91 million for the quarter, compared to analysts' expectations of $0.82 million. Delcath Systems had a negative trailing twelve-month return on equity of 1,396.28% and a negative net margin of 757.05%. During the same period last year, the firm posted ($0.94) EPS.

When did Delcath Systems' stock split?

Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is Delcath Systems' stock symbol?

Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH."

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Delcath Systems' stock price today?

One share of DCTH stock can currently be purchased for approximately $3.75.

How much money does Delcath Systems make?

Delcath Systems (NASDAQ:DCTH) has a market capitalization of $37.69 million and generates $3.56 million in revenue each year. The company earns $-25,650,000.00 in net income (profit) each year or ($3.79) on an earnings per share basis.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The official website for the company is delcath.com. The company can be reached via phone at 212-489-2100, via email at investorrelations@delcath.com, or via fax at 212-489-2102.

This page (NASDAQ:DCTH) was last updated on 1/29/2023 by MarketBeat.com Staff